EU Pharma Package Hits the Final Stretch—but Can Negotiators Agree? Life Sciences Intellectual Property Review

Partner Jackie Mulryne discussed the EU Pharma Package in the Life Sciences Intellectual Property Review, highlighting proposed changes to data protection, orphan drug exclusivity, and access obligations.

Jackie explained how these reforms could reshape incentives for innovation and market strategies, urging companies to stay engaged as negotiations aim for year-end resolution.

Read the full Life Sciences Intellectual Property Review article >>
Subscription may be required.